MedTrace Logo

A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT)

NCT00307814 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 519

Last updated 2011-05-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness and safety of less frequent dosing of PROCRIT (Epoetin alfa) in patients with anemia due to Chronic Kidney Disease (CKD) as assessed by hemoglobin maintenance, adverse events and health-related quality of life.

Conditions

  • Anemia
  • Chronic Renal Insufficiency

Interventions

DRUG

Epoetin Alfa

Sponsors & Collaborators

  • Ortho Biotech Products, L.P.

    lead INDUSTRY

Principal Investigators

  • Ortho Biotech Products, L.P. Clinical Trial · Ortho Biotech Products, L.P.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Completion
2004-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00307814 on ClinicalTrials.gov